Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Breast Cancer
Interventions
DRUG

Bevacizumab

IV 15mg/kg 21 days

DRUG

Cyclophosphamide

500mg per meter squared, IV every 21 days

DRUG

Docetaxel

60 mg per meter squared, IV every 21 days

Trial Locations (1)

72205

University of Arkansas for Medical Sciences, Little Rock

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Arkansas

OTHER